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S226 Poster Session IResults: 18 patients withHLA-Ab against UCB unit 1 (9), UCB unit
2 (2) or both UCB units (7) were identified. No differences in cell
doses, viability or baseline characteristics were noted between
patients with/without HLA-Ab. The presence of HLA-Ab was asso-
ciated with an increased risk of graft failure (HLA-Ab against either
UCB unit: OR 8.67, 95%CI 1.89–39.68, p 5 0.0055; HLA-Ab
against both UCB units: OR 16.27, 2.82–93.87, p 5 0.0034). Neu-
trophil engraftment was delayed in the presence of HLA-Ab (median
21 vs. 29 days, p5 0.04) and fewer patients engrafted platelets in the
presence of HLA-Ab (76.4% vs. 50%, p 5 0.03). HLA-Ab against
UCB unit 1 was associated with UCB unit 2 dominance (OR 9.43,
95%CI 1.16–76.47, p 5 0.015), while HLA-Ab against UCB unit
2 was associated with a non-significant trend toward UCB unit 1
dominance (OR 2.70, 95%CI 0.63–12.5, p 5 0.28). Overall survival
was inferior in the presence of HLA-Ab against UCB unit 2 (p 5
0.044) or both UCB units (p5 0.027), but not with HLA-Ab against
UCB unit 1 only.
Conclusions: In DUBCT, the presence of HLA-Ab increases the
risk of graft rejection, prolongs time to engraftment, predicts UCB
dominance and is associated with inferior outcome.HLA-Ab screen-
ing should be incorporated into UCB unit selection strategies in
DUCBT.198
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Through an in vivo zebrafish screen for modulators of hematopoi-
etic stem cell (HSC) development, a small molecule, 16,16-dimethyl
prostaglandin E2 (FT1050) was identified (North, 2007). FT1050
was shown to enhance the engraftment potential of HSCs from mu-
rine bone marrow (mBM) or human umbilical cord blood (hCB) in
murine engraftment models through an increase in proliferation,
survival, migration and homing after a brief (1 to 2 hr) ex vivo treat-
ment (North, 2007; North, 2009; Hoggatt, 2009; North, Goessling,
Zon, unpublished data).We further optimized the ex vivo hCB incu-
bation protocol using whole genome expression arrays and deter-
mined that HSC-containing cell products should be incubated
with 10mMFT1050 for 2 hrs at 37C to obtain the optimal response.
In addition, we observed that FT1050 induces similar gene expres-
sion changes in hBM- and mobilized peripheral blood-derived
CD341 cells. Subsequent functional studies demonstrated that in
keeping with increases of up to 18-fold in CXCR4 gene expression,
cell surface CXCR4 protein expression was also significantly in-
creased. One hour after treatment with10mM FT1050 for 2 hrs at
37C, 4861.9% of CB CD341 cells expressed CXCR4 compared
to 3.560.01% in DMSO control (p\0.05). In vivo CFU-S12 anal-
ysis showed that treatment of mBM cells with 10mM FT1050 for 2
hrs at 37C resulted in greater proliferation with a statistically signif-
icant increase in colony formation, 11.561.4, compared to 460.8
colonies with DMSO control (p\ 0.001). This short-term ex vivo
incubation protocol, 10mM FT1050 for 2 hrs at 37C, has been in-
troduced into an ongoing Phase Ib clinical trial in adults with hema-
tologic malignancies receiving a nonmyeloablative conditioning
(melphalan, fludarabine and ATG) followed by double hCB trans-
plantation, in which one of the two hCBs is incubated with
FT1050 prior to infusion. The primary objective of the study is to
determine the safety of FT1050 treatment of hCB. Preliminary
data demonstrate that this ex vivo incubation can be reliably per-
formed at the clinical site on the day of infusion with good cell recov-
ery and viability. 11 subjects with a median age of 44 years have been
accrued to date, of which two have been treated using the optimized
ex vivo incubation protocol. 10 of 11 patients have achieved an ANC
. 500 beforeDay 42. Transplant relatedmortality has been lowwithone death at Day 53 from respiratory failure. 9 patients are alive, of
which 7 are disease-free. Accrual is ongoing.199
ALLOGENEIC TRANSPLANTATION USING HAPLOIDENTICAL DONOR VER-
SUS UNRELATED CORD BLOOD DONOR: A SINGLE CENTER RETROSPEC-
TIVE STUDY
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We have performed a retrospective comparison of pediatric pa-
tients with leukemia receiving a haplo transplant (n 5 29) or
UCBT (n 5 38) in Ni~no Jesus Children’s Hospital since 1996 to
2010. There were not significant differences in immunophenotype,
disease status and antecedent of prior autograft. However, haplo re-
cipients tended to be older and of male gender.
Engraftment failure was significantly higher following UCBT
965% compared to 765% in haplo transplants (p5 0.001). Median
neutrophil engraftment were at 13 days for haplo and 20 days for
UCBT (p 5 0.01) and platelet engraftment at 11 days for haplo
and 56 days for UCBT (p 5 0.0001). Supportive care (transfusions,
antibiotics, parenteral nutrition and hospitalization days) were sig-
nificantly higher for cord blood transplants.
TRM and acute GVHD (more than grade II) incidence was higher
in UCBT compared to haplo transplants. There were not significant
differences in chronic GVHD and relapse probability between the
two groups. Results are summarized in table 1.
Disease-free survival (DFS) with a median follow-up of 16 months
(range: 1-42) and 57 months (range: 1-150) were of 44610% and
3267% (p 5 0.03) for haplo transplants and UCBT respectively.
When we analyzed AML, there were not differences in DFS with
both type of donor (p 5 0.6). However, DFS for ALL was better
with haplo (41613%) against cord blood (266 9%) (p 5 0.03). Ac-
cording to phase of disease, DFS was similar in early phase (p5 0.7),
but in advanced phase outcomewas better with haplo (37614%) ver-
sus cord blood (2168%) (p 5 0.05).
Multivariate analysis of DFS showed that the main prognostic fac-
tors were disease status at transplant (HR 2.49, p 5 0.02), chronic
GVHD (HR 0.21, p 5 0.0001) and source of stem cells (HR 5.75,
p 5 0.001).
In conclusion, our data suggest that haploidentical donor is a good
alternative for patients lacking an HLA identical donor.
Table 1. Results.
aGVHD >II TRM Relapse DFSHaplo (n529) 19±7% 25±9% 48±12% 44±10%
UCB (n538) 44±10% 57±9% 25±9% 32±7%
P 0.03 0.05 0.7 0.03200
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Background: CD341 stem cell selection depletes T cells responsi-
ble for severe aGVHD (Lang et al., Blood, 2003). CD341 selected
grafts have been associated with delayed IR (Ball et al, BMT, 2005,
Eyrich et al, BJH, 2001). Delayed IR is a significant risk factor for
